Iqirvo
My Prescription
Payment
Select pharmacy
$12,347.54
Print or send this coupon to your phone
WalmartPowered byAbout Iqirvo
Drug Details
Elafibranor, marketed as Iqirvo, is approved by the FDA for the treatment of primary biliary cholangitis (PBC) in adults. PBC is a liver condition caused by damaged bile ducts, leading to an accumulation of bile that can harm the liver. Elafibranor functions as a peroxisome proliferator-activated receptor (PPAR) agonist, which helps reduce the production of bile acid by the liver. Available in 80 mg tablets, it is taken orally once a day and can be used alone or in combination with ursodiol (Actigall). While it is effective in decreasing bile production, its impact on extending life or improving liver health in PBC patients is not yet established. Common side effects include weight gain, diarrhea, and stomach pain. Always consult healthcare professionals before starting any medication.
Price history for Iqirvo
30 Tablets, 80MG
Average retail price for Iqirvo
Average SaveHealth price for Iqirvo
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Iqirvo dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 80MG | 30 Tablets | $12,347.54 | $411.59 |
Iqirvo FAQs
Iqirvo is used for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
The cost of Iqirvo can vary depending on factors such as the pharmacy, location, insurance coverage, and any available discounts or patient assistance programs. It is recommended to check with local pharmacies or consult with a healthcare provider for the most accurate and up-to-date pricing information.
Iqirvo and Livdelzi are both medications used to treat specific conditions, but they differ in their active ingredients and the conditions they are designed to treat. Iqirvo contains the active ingredient bimekizumab and is used primarily for the treatment of moderate to severe plaque psoriasis. Livdelzi, on the other hand, contains the active ingredient deucravacitinib and is also used for treating moderate to severe plaque psoriasis. The main difference lies in their mechanisms of action; bimekizumab is a monoclonal antibody that targets interleukin-17A and interleukin-17F, while deucravacitinib is a selective tyrosine kinase 2 (TYK2) inhibitor. This difference in action may influence the choice of treatment based on patient-specific factors and physician recommendations.